Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionCombination of glycopyrrolate (PT001), a long-acting muscarinic antagonist (LAMA), formoterol fumarate (PT005), a long-acting beta-2 agonist (LABA), and an inhaled corticosteroid (ICS) delivered via a single metered-dose hydrofluoroalkane (HFA) inhaler
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today